NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced that it intends to divest its U.S. and Canadian consumer medicines business. Over the coming weeks, the company will contact prospective buyers for this business.
The company's consumer medicines businesses in Japan, China, Latin America Europe, Middle East and Africa are not included in this divestiture. These businesses remain an important part of the company's pharmaceutical business within each region.
Bristol-Myers Squibb's primary consumer medicine brands in the U.S. and Canada are Excedrin®, Keri®, Choice® and Comtrex®. For the year ended December 31, 2003, sales of consumer medicines brands in the U.S. and Canada totaled approximately $240 million.
Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. Specifically, there can be no guarantee that the potential transaction described in this release will be completed. For further details and a discussion of this and other risks and uncertainties, please see the company's 2003 Annual Report on Form 10-K/A and the company's periodic reports on Form 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.